As TNBCs do not express ER, PR, or HER2, specific endocrine therapies (tamoxifen) or targeted therapies (trastuzumab) benefiting other breast cancer subtypes are ineffective in TNBCs. This evidence concerns the gene ESR1 and breast cancer.